The French-Belgian medtech company utilizes a portable headset to capture up to 800 infrared images per eye per second, extracting oculomotor biomarkers that can indicate neurological disorders like Parkinson’s, Alzheimer’s, and multiple sclerosis years before clinical symptoms emerge. After receiving CE certification in January 2025, it aims for FDA clearance in 2026.
neuroClues, a French-Belgian medtech firm, secured a €10 million Series A for its AI-powered eye-tracking device designed for early diagnosis of neurological disorders. This funding round follows the CE certification received in January 2025 for its Class IIa medical device, allowing European market use. Having raised over €22 million since its 2020 founding, neuroClues has developed a portable headset that captures up to 800 infrared images per eye per second as patients visually follow a screen target. The AI models then quickly extract oculomotor biomarkers, providing neurologists with quantifiable measures indicating potential neurological disorders like Parkinson’s, Alzheimer’s, and multiple sclerosis before notable symptoms appear. The device requires no calibration and suits standard medical consultations.
Founded in 2020 as P3Lab by Antoine Pouppez, Pierre Daye, and Pierre Pouget—experienced neuroscience researchers—the company draws on extensive research linking eye movements to neurological conditions, a concept dating back to 1905. Despite numerous studies affirming clinical relevance, widespread adoption was hindered by costly or imprecise hardware. neuroClues aims to appeal to the 2.3 million physicians who assess brain health through conventional methods, addressing the notable diagnostic gap in Parkinson’s treatment, where misdiagnosis rates are high and diagnosis delays significant neuronal loss. Estimates predict the Parkinson’s population doubling to 13 million by 2040.
neuroClues’ device is integrated into the Iceberg cohort study at Paris Brain Institute’s La Salpêtrière Hospital, seeking early Parkinson’s biomarkers under Professors Marie Vidailhet and Stéphane Lehéricy. Previous findings showcased the device’s ability to detect preclinical Parkinson’s markers years before traditional diagnostic methods. Before its Series A, neuroClues accumulated €4.7 million in a 2021 seed round, €2.5 million in grants from the European Commission’s EIC Accelerator, with additional EIC funding commitments, and €5 million in a pre-Series A in April 2024 from White Fund, EIC Accelerator, Invest.BW, and notable business angels. The new funding will expand the commercial team, support FDA clearance pursuit for 2026, and bolster European market growth. The headquarters and manufacturing are in Louvain-la-Neuve, Belgium, with an office in Paris’s iPEPS incubator.